Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go

Thomas Gevaert, Alessia Cimadamore, Markus Eckstein, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi

Research output: Contribution to journalReview article

Original languageEnglish (US)
Pages (from-to)2199-2202
Number of pages4
JournalFuture Oncology
Volume15
Issue number19
DOIs
StatePublished - Jul 1 2019

Fingerprint

Microbiota
Immunotherapy
Biomarkers
Lymphocytes
Carcinoma
Therapeutics
MPDL3280A

Keywords

  • atezolizumab
  • basal-type
  • genitourinary tumors
  • immunotherapy
  • luminal-type
  • lymphocytes
  • microbiome
  • PD-L1
  • urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gevaert, T., Cimadamore, A., Eckstein, M., Scarpelli, M., Lopez-Beltran, A., Cheng, L., & Montironi, R. (2019). Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go. Future Oncology, 15(19), 2199-2202. https://doi.org/10.2217/fon-2019-0217

Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma : Where we stand and where we go. / Gevaert, Thomas; Cimadamore, Alessia; Eckstein, Markus; Scarpelli, Marina; Lopez-Beltran, Antonio; Cheng, Liang; Montironi, Rodolfo.

In: Future Oncology, Vol. 15, No. 19, 01.07.2019, p. 2199-2202.

Research output: Contribution to journalReview article

Gevaert, T, Cimadamore, A, Eckstein, M, Scarpelli, M, Lopez-Beltran, A, Cheng, L & Montironi, R 2019, 'Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go', Future Oncology, vol. 15, no. 19, pp. 2199-2202. https://doi.org/10.2217/fon-2019-0217
Gevaert, Thomas ; Cimadamore, Alessia ; Eckstein, Markus ; Scarpelli, Marina ; Lopez-Beltran, Antonio ; Cheng, Liang ; Montironi, Rodolfo. / Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma : Where we stand and where we go. In: Future Oncology. 2019 ; Vol. 15, No. 19. pp. 2199-2202.
@article{d959e9806f4942489fe3350c08c1cfb9,
title = "Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go",
keywords = "atezolizumab, basal-type, genitourinary tumors, immunotherapy, luminal-type, lymphocytes, microbiome, PD-L1, urothelial carcinoma",
author = "Thomas Gevaert and Alessia Cimadamore and Markus Eckstein and Marina Scarpelli and Antonio Lopez-Beltran and Liang Cheng and Rodolfo Montironi",
year = "2019",
month = "7",
day = "1",
doi = "10.2217/fon-2019-0217",
language = "English (US)",
volume = "15",
pages = "2199--2202",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "19",

}

TY - JOUR

T1 - Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma

T2 - Where we stand and where we go

AU - Gevaert, Thomas

AU - Cimadamore, Alessia

AU - Eckstein, Markus

AU - Scarpelli, Marina

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Montironi, Rodolfo

PY - 2019/7/1

Y1 - 2019/7/1

KW - atezolizumab

KW - basal-type

KW - genitourinary tumors

KW - immunotherapy

KW - luminal-type

KW - lymphocytes

KW - microbiome

KW - PD-L1

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85069520160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069520160&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0217

DO - 10.2217/fon-2019-0217

M3 - Review article

C2 - 31213082

AN - SCOPUS:85069520160

VL - 15

SP - 2199

EP - 2202

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 19

ER -